Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634763 | 0.80 | JAK2 (0.57) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL13535983 | 0.78 | NUDT1 (0.57) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL1810011 | 0.78 | JAK2 (0.56) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL3260453 | 0.78 | JAK2 (0.72) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL2640521 | 0.77 | JAK2 (0.54) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL21083114 | 0.77 | NUDT1 (0.69) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL18952791 | 0.77 | JAK2 (0.47) | JAK2NUDT1JAK3PTK2PARP1 | |
| SCHEMBL18341214 | 0.77 | JAK2 (0.50) | JAK2NUDT1JAK3PTK2JAK1 | |
| SCHEMBL10001046 | 0.73 | JAK2 (0.42) | JAK2NUDT1PTK2MAP4K4PAK4 | |
| SCHEMBL21078019 | 0.73 | JAK2 (0.57) | JAK2JAK3PTK2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2438066-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES | Cephalon, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296312-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | JAK2, JAK1, JAK3 | JAK2 1/4885NUDT1 2601/4885JAK3 3/4885 |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | JAK2 31/4885NUDT1 736/4885JAK3 175/4885 |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, TYK2, LTK | JAK2 40/4885NUDT1 2035/4885JAK3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.